中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 8
Aug.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(8): 1677-1681

The role of necroptosis in liver fibrosis

DOI: 10.12449/JCH240827
  • 1.

    Central Laboratory，The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine，Chengdu 610072，China

  • 2.

    School of Clinical Medicine，Chengdu University of Traditional Chinese Medicine，Chengdu 610072，China

Research funding:

General Project of National Natural Science Foundation of China (82274323)

More Information
  • Corresponding author: LI Hui， 1400124746@qq.com （ORCID： 0000-0002-5919-1396）
  • Received Date: 2024-01-08
  • Accepted Date: 2024-03-13
  • Published Date: 2024-08-25
    Abstract
  • As a crucial link in the progression of various chronic liver diseases to liver cirrhosis， liver fibrosis affects the prognosis and outcome of chronic liver diseases. Necrotosis is a novel pattern of programmed cell death （PCD）， and studies have shown that it plays an important role in the pathophysiology of various diseases and is considered a potential target for improving liver fibrosis. Necroptosis of various types of intrahepatic cells （including hepatocytes， hepatic stellate cells， liver macrophages， and hepatic sinusoidal endothelial cells） can promote or inhibit liver fibrosis. This article elaborates on the above mechanisms and discusses the therapeutic strategies for targeting liver fibrosis mediated by necroptosis.

     

    • FullText(HTML)
  • loading
    • References(40)
  • [1]
    YANG X, LI Q, LIU WT, et al. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: From pathogenesis to treatment[J]. Cell Mol Immunol, 2023, 20( 6): 583- 599. DOI: 10.1038/s41423-023-00983-5.
    [2]
    HUANG DQ, TERRAULT NA, TACKE F, et al. Global epidemiology of cirrhosis-aetiology, trends and predictions[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 6): 388- 398. DOI: 10.1038/s41575-023-00759-2.
    [3]
    ORNOS ED, MURILLO KJ, ONG JP. Liver diseases: Perspective from the Philippines[J]. Ann Hepatol, 2023, 28( 3): 101085. DOI: 10.1016/j.aohep.2023.101085.
    [4]
    ZHANG WB, FAN WL, GUO J, et al. Osmotic stress activates RIPK3/MLKL-mediated necroptosis by increasing cytosolic pH through a plasma membrane Na+/H+ exchanger[J]. Sci Signal, 2022, 15( 734): eabn5881. DOI: 10.1126/scisignal.abn5881.
    [5]
    GALLUZZI L, KEPP O, CHAN FKM, et al. Necroptosis: Mechanisms and relevance to disease[J]. Annu Rev Pathol, 2017, 12: 103- 130. DOI: 10.1146/annurev-pathol-052016-100247.
    [6]
    ANNIBALDI A, MEIER P. Checkpoints in TNF-induced cell death: Implications in inflammation and cancer[J]. Trends Mol Med, 2018, 24( 1): 49- 65. DOI: 10.1016/j.molmed.2017.11.002.
    [7]
    TING AT, BERTRAND MJM. More to life than NF-κB in TNFR1 signaling[J]. Trends Immunol, 2016, 37( 8): 535- 545. DOI: 10.1016/j.it.2016.06.002.
    [8]
    ZHANG YY, SU SS, ZHAO SB, et al. RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necrosome[J]. Nat Commun, 2017, 8: 14329. DOI: 10.1038/ncomms14329.
    [9]
    WEI S, ZHOU HM, WANG Q, et al. RIP3 deficiency alleviates liver fibrosis by inhibiting ROCK1-TLR4-NF-κB pathway in macrophages[J]. FASEB J, 2019, 33( 10): 11180- 11193. DOI: 10.1096/fj.201900752R.
    [10]
    ROYCHOWDHURY S, MCCULLOUGH RL, SANZ-GARCIA C, et al. Receptor interacting protein 3 protects mice from high-fat diet-induced liverinjury[J]. Hepatology, 2016, 64( 5): 1518- 1533. DOI: 10.1002/hep.28676.
    [11]
    WU XQ, POULSEN KL, SANZ-GARCIA C, et al. MLKL-dependent signaling regulates autophagic flux in a murine model of non-alcohol-associated fatty liver and steatohepatitis[J]. J Hepatol, 2020, 73( 3): 616- 627. DOI: 10.1016/j.jhep.2020.03.023.
    [12]
    MAJDI A, AOUDJEHANE L, RATZIU V, et al. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease[J]. J Hepatol, 2020, 72( 4): 627- 635. DOI: 10.1016/j.jhep.2019.11.008.
    [13]
    SCHUPPAN D, SURABATTULA R, WANG XY. Determinants of fibrosis progression and regression in NASH[J]. J Hepatol, 2018, 68( 2): 238- 250. DOI: 10.1016/j.jhep.2017.11.012.
    [14]
    KOSCHEL J, NISHANTH G, JUST S, et al. OTUB1 prevents lethal hepatocyte necroptosis through stabilization of c-IAP1 during murine liver inflammation[J]. Cell Death Differ, 2021, 28( 7): 2257- 2275. DOI: 10.1038/s41418-021-00752-9.
    [15]
    MOHAMMED S, THADATHIL N, SELVARANI R, et al. Necroptosis contributes to chronic inflammation and fibrosis in aging liver[J]. Aging Cell, 2021, 20( 12): e13512. DOI: 10.1111/acel.13512.
    [16]
    ZHANG BC, LI MD, YIN RN, et al. O-GlcNAc transferase suppresses necroptosis and liver fibrosis[J]. JCI Insight, 2019, 4( 21): e127709. DOI: 10.1172/jci.insight.127709.
    [17]
    LIU Q, LEI XH, CAO ZY, et al. TRPM8 deficiency attenuates liver fibrosis through S100A9-HNF4α signaling[J]. Cell Biosci, 2022, 12( 1): 58. DOI: 10.1186/s13578-022-00789-4.
    [18]
    ZHOU J, ZHAO Y, GUO YJ, et al. A rapid juvenile murine model of nonalcoholic steatohepatitis(NASH): Chronic intermittent hypoxia exacerbates Western diet-induced NASH[J]. Life Sci, 2021, 276: 119403. DOI: 10.1016/j.lfs.2021.119403.
    [19]
    GUERRA S, MOCCIARO G, GASTALDELLI A. Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis[J]. Eur J Clin Invest, 2022, 52( 3): e13695. DOI: 10.1111/eci.13695.
    [20]
    GUO R, JIA XH, DING ZB, et al. Loss of MLKL ameliorates liver fibrosis by inhibiting hepatocyte necroptosis and hepatic stellate cell activation[J]. Theranostics, 2022, 12( 11): 5220- 5236. DOI: 10.7150/thno.71400.
    [21]
    HUANG J, LI RB, WANG CB. Molecular mechanism of UPRmt in ameliorating alcohol-induced hepatocyte necroptosis[J]. Acad J Chin PLA Med Sch, 2023, 44( 6): 700- 707. DOI: 10.3969/j.issn.2095-5227.2023.06.020.

    黄嘉, 李芮冰, 王成彬. UPRmt改善乙醇诱导的肝细胞坏死性凋亡的分子机制研究[J]. 解放军医学院学报, 2023, 44( 6): 700- 707. DOI: 10.3969/j.issn.2095-5227.2023.06.020.
    [22]
    JIA Y, WANG FX, GUO Q, et al. Curcumol induces RIPK1/RIPK3 complex-dependent necroptosis via JNK1/2-ROS signaling in hepatic stellate cells[J]. Redox Biol, 2018, 19: 375- 387. DOI: 10.1016/j.redox.2018.09.007.
    [23]
    OH JH, SAEED WK, KIM HY, et al. Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis[J]. J Gastroenterol Hepatol, 2023, 38( 12): 2206- 2214. DOI: 10.1111/jgh.16368.
    [24]
    NOVO E, MARRA F, ZAMARA E, et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: Resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans[J]. Gut, 2006, 55( 8): 1174- 1182. DOI: 10.1136/gut.2005.082701.
    [25]
    LU CF, XU WX, ZHANG F, et al. Study of Dihydroartemisinin on inducing necroptosis through activating Nrf2 in hepatic stellate cells in vitro[J]. China J Tradit Chin Med Pharm, 2016, 31( 5): 1919- 1925.

    陆春风, 许文萱, 张峰, 等. 双氢青蒿素通过激活Nrf2促进肝星状细胞坏死性凋亡的研究[J]. 中华中医药杂志, 2016, 31( 5): 1919- 1925.
    [26]
    SUN SM, HUAN S, LI ZH, et al. Curcumol alleviates liver fibrosis by inducing endoplasmic reticulum stress-mediated necroptosis of hepatic stellate cells through Sirt1/NICD pathway[J]. Peer J, 2022, 10: e13376. DOI: 10.7717/peerj.13376.
    [27]
    KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
    [28]
    HU MY, WANG Y, LIU ZS, et al. Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis[J]. Nat Nanotechnol, 2021, 16( 4): 466- 477. DOI: 10.1038/s41565-020-00836-6.
    [29]
    WU XQ, FAN XD, MCMULLEN MR, et al. Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis[J]. Hepatology, 2023, 77( 3): 902- 919. DOI: 10.1002/hep.32612.
    [30]
    GAUTHERON J, VUCUR M, REISINGER F, et al. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis[J]. EMBO Mol Med, 2014, 6( 8): 1062- 1074. DOI: 10.15252/emmm.201403856.
    [31]
    NI Y, LI JM, LIU MK, et al. Pathological process of liver sinusoidal endothelial cells in liver diseases[J]. World J Gastroenterol, 2017, 23( 43): 7666- 7677. DOI: 10.3748/wjg.v23.i43.7666.
    [32]
    POISSON J, LEMOINNE S, BOULANGER C, et al. Liver sinusoidal endothelial cells: Physiology and role in liver diseases[J]. J Hepatol, 2017, 66( 1): 212- 227. DOI: 10.1016/j.jhep.2016.07.009.
    [33]
    LAFOZ E, RUART M, ANTON A, et al. The endothelium as a driver of liver fibrosis and regeneration[J]. Cells, 2020, 9( 4): 929. DOI: 10.3390/cells9040929.
    [34]
    YAN ML, LI H, XU SY, et al. Targeting endothelial necroptosis disrupts profibrotic endothelial-hepatic stellate cells crosstalk to alleviate liver fibrosis in nonalcoholic steatohepatitis[J]. Int J Mol Sci, 2023, 24( 14): 11313. DOI: 10.3390/ijms241411313.
    [35]
    ZHENG F, DEVOOGDT N, SPARKES A, et al. Monitoring liver macrophages using nanobodies targeting Vsig4: Concanavalin A induced acute hepatitis as paradigm[J]. Immunobiology, 2015, 220( 2): 200- 209. DOI: 10.1016/j.imbio.2014.09.018.
    [36]
    LI JX, FENG JM, WANG Y, et al. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury[J]. Cell Death Dis, 2014, 5( 6): e1278. DOI: 10.1038/cddis.2014.241.
    [37]
    WANG SG, NI HM, DORKO K, et al. Increased hepatic receptor interacting protein kinase 3 expression due to impaired proteasomal functions contributes to alcohol-induced steatosis and liver injury[J]. Oncotarget, 2016, 7( 14): 17681- 17698. DOI: 10.18632/oncotarget.6893.
    [38]
    GÜNTHER C, HE GW, KREMER AE, et al. The pseudokinase MLKL mediates programmed hepatocellular necrosis independently of RIPK3 during hepatitis[J]. J Clin Invest, 2016, 126( 11): 4346- 4360. DOI: 10.1172/JCI87545.
    [39]
    LIM EJ, KHOBAR KE, CHIN R, et al. Hepatitis C virus-induced hepatocyte cell death and protection by inhibition of apoptosis[J]. J Gen Virol, 2014, 95( Pt 10): 2204- 2215. DOI: 10.1099/vir.0.065862-0.
    [40]
    HUANG LJ, MAO DW, ZHANG RZ, et al. Research advances in traditional Chinese medicine regulation of programmed cell death in intervening against hepatic fibrosis[J]. J Clin Hepatol, 2024, 40( 1): 161- 168. DOI: 10.12449/JCH240127.

    黄良江, 毛德文, 张荣臻, 等. 中医药调控程序性细胞死亡干预肝纤维化的研究进展[J]. 临床肝胆病杂志, 2024, 40( 1): 161- 168. DOI: 10.12449/JCH240127.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (119) PDF downloads(19) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return